$VERU
Veru Inc Stock $veru

$veru Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000086389419000007 Filed on May 15, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$9.727M	$6.976M	$2.573M
YoY Change	76.8%	171.14%	6.76%
Cost Of Revenue	$3.156M	$2.367M	$1.375M
YoY Change	30.0%	72.17%	21.68%
Gross Profit	$6.571M	$4.609M	$1.198M
YoY Change	113.75%	284.73%	-6.41%
Gross Profit Margin	67.56%	66.07%	46.56%
Selling, General & Admin	$3.547M	$3.823M	$3.818M
YoY Change	-11.86%	0.14%	57.76%
% of Gross Profit	53.98%	82.95%	318.69%
Research & Development	$4.866M	$2.911M	$2.077M
YoY Change	28.48%	40.15%	44.22%
% of Gross Profit	74.05%	63.15%	173.36%
Depreciation & Amortization	$130.0K	$110.0K	$120.0K
YoY Change	18.18%	-8.33%	-7.69%
% of Gross Profit	1.98%	2.39%	10.02%
Operating Expenses	$8.413M	$6.733M	$5.894M
YoY Change	4.66%	14.23%	53.1%
Operating Profit	-$1.842M	-$2.125M	-$4.697M
YoY Change	-62.9%	-54.76%	82.75%
Interest Expense	$1.091M	$1.258M	$350.6K
YoY Change	-20.93%	258.9%	-1852.98%
% of Operating Profit
Other Income/Expense, Net	-$932.5K	-$1.884M	-$437.1K
YoY Change	-47.0%	331.1%	4270.84%
Pretax Income	-$2.775M	-$4.009M	-$5.134M
YoY Change	-58.74%	-21.91%	97.45%
Income Tax	-$458.00	$25.17K	-$1.302M
% Of Pretax Income
Net Earnings	-$2.774M	-$4.034M	-$3.831M
YoY Change	-65.02%	5.29%	115.24%
Net Earnings / Revenue	-28.52%	-57.83%	-148.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$44.02K	-$64.20K	-$71.78K
COMMON SHARES
Basic Shares Outstanding	62.79M	62.78M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.000M	$5.900M	$9.000M
YoY Change	42.86%	-34.44%	718.18%
Cash & Equivalents	$8.039M	$5.897M	$8.972M
Short-Term Investments
Other Short-Term Assets	$1.200M	$1.200M	$600.0K
YoY Change	20.0%	100.0%	-14.29%
Inventory	$3.131M	$2.998M	$3.600M
Prepaid Expenses
Receivables	$4.767M	$4.027M	$2.900M
Other Receivables	$0.00	$0.00	$100.0K
Total Short-Term Assets	$17.14M	$14.14M	$16.20M
YoY Change	32.89%	-12.7%	38.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$314.7K	$320.8K	$500.0K
YoY Change	-37.06%	-35.84%	-28.57%
Goodwill	$6.879M	$6.879M
YoY Change
Intangibles	$20.25M	$20.32M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$684.1K	$776.2K	$14.10M
YoY Change	-94.61%	-94.5%	53.26%
Total Long-Term Assets	$36.70M	$36.87M	$42.00M
YoY Change	-9.61%	-12.22%	-7.69%
TOTAL ASSETS
Total Short-Term Assets	$17.14M	$14.14M	$16.20M
Total Long-Term Assets	$36.70M	$36.87M	$42.00M
Total Assets	$53.84M	$51.01M	$58.20M
YoY Change	0.64%	-12.35%	1.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.135M	$2.525M	$3.500M
YoY Change	-10.43%	-27.85%	150.0%
Accrued Expenses	$3.900M	$2.900M	$2.300M
YoY Change	85.71%	26.09%	15.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.700M	$5.800M	$3.900M
YoY Change	-26.56%	48.72%
Total Short-Term Liabilities	$11.66M	$11.27M	$10.60M
YoY Change	-8.16%	6.34%	211.76%
LONG-TERM LIABILITIES
Long-Term Debt	$6.300M	$5.100M	$6.200M
YoY Change	31.25%	-17.74%
Other Long-Term Liabilities	$30.00K	$30.00K	$100.0K
YoY Change	-70.0%	-70.0%	-92.31%
Total Long-Term Liabilities	$30.00K	$30.00K	$6.300M
YoY Change	-99.39%	-99.52%	384.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.66M	$11.27M	$10.60M
Total Long-Term Liabilities	$30.00K	$30.00K	$6.300M
Total Liabilities	$19.10M	$17.47M	$16.90M
YoY Change	8.55%	3.36%	196.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.16M	-$64.38M
YoY Change
Common Stock	$670.0K	$649.7K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.807M	$7.807M
YoY Change
Treasury Stock Shares	$2.184M	$2.184M
Shareholders Equity	$34.74M	$33.54M	$41.33M
YoY Change
Total Liabilities & Shareholders Equity	$53.84M	$51.01M	$58.20M
YoY Change	0.64%	-12.35%	1.75%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$2.774M	-$4.034M	-$3.831M
YoY Change	-65.02%	5.29%	115.24%
Depreciation, Depletion And Amortization	$130.0K	$110.0K	$120.0K
YoY Change	18.18%	-8.33%	-7.69%
Cash From Operating Activities	-$530.0K	-$2.490M	-$4.480M
YoY Change	-88.35%	-44.42%	100.9%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	$0.00	$0.00
YoY Change	40.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$70.00K	$0.00	$0.00
YoY Change	40.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.740M	-590.0K	9.880M
YoY Change	128.33%	-105.97%
NET CHANGE
Cash From Operating Activities	-530.0K	-2.490M	-4.480M
Cash From Investing Activities	-70.00K	0.000	0.000
Cash From Financing Activities	2.740M	-590.0K	9.880M
Net Change In Cash	2.140M	-3.080M	5.400M
YoY Change	-162.94%	-157.04%	-341.07%
FREE CASH FLOW
Cash From Operating Activities	-$530.0K	-$2.490M	-$4.480M
Capital Expenditures	-$70.00K	$0.00	$0.00
Free Cash Flow	-$460.0K	-$2.490M	-$4.480M
YoY Change	-89.78%	-44.42%	101.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3985217
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000863894
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62790208
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	VERU INC.
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Trading Symbol TradingSymbol	veru
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3226036
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2525162
CY2019Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4076745
CY2019Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	4027235
CY2019Q1	us-gaap	Accretion Expense AccretionExpense	123946
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3901418
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-581519
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-581519
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95496506
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105666943
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	411848
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	913465
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	38103
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36161
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36201
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36201
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5570
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	26704
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1107622
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	137631
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	154617
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77000
CY2018Q3	us-gaap	Assets Assets	48452639
CY2019Q1	us-gaap	Assets Assets	51012054
CY2019Q1	us-gaap	Assets Current AssetsCurrent	14142880
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	496209
CY2018Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	3972632
CY2018Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4046733
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3972632
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4027235
	us-gaap	Accretion Expense AccretionExpense	27278
CY2018Q1	us-gaap	Accretion Expense AccretionExpense	27278
	us-gaap	Accretion Expense AccretionExpense	216297
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5570
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	54570
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	317747
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	317747
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2265828
CY2018Q3	us-gaap	Assets Current AssetsCurrent	11182516
CY2019Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5286651
CY2019Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22243212
CY2019Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12960941
CY2019Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	8057926
CY2019Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10621438
CY2019Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2468061
CY2019Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7674290
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3628736
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1273685
CY2018Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-385395
CY2019Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-199521
CY2019Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9282271
CY2019Q1	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	85044
CY2019Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 1 – Basis of Presentation</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, these statements do not include all the disclosures normally required by U.S. GAAP for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="display: inline;">September 30, 2018</font><font style="display: inline;">. The accompanying condensed consolidated balance sheet as of </font><font style="display: inline;">September 30, 2018</font><font style="display: inline;"> has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations for the three and six months ended March 31, 2019 and cash flows for the </font><font style="display: inline;">six months ended March 31, 2019</font><font style="display: inline;"> are not necessarily indicative of the results to be expected for any future period or for the fiscal year ending </font><font style="display: inline;">September 30, 201</font><font style="display: inline;">9</font><font style="display: inline;">.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Principles of consolidation and nature of operations</font><font style="display: inline;">: Veru Inc. is </font><font style="display: inline;color:#000000;">referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” </font><font style="display: inline;">The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Aspen Park Pharmaceuticals, Inc. (“APP”) and The Female Health Company Limited, and The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”), and The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”). All significant intercompany transactions and accounts have been eliminated in consolidation. Prior to the completion of the October 31, 2016 acquisition (the “APP Acquisition”) of APP through the merger of a wholly owned subsidiary of the Company into APP, the Company had been a single product company engaged in marketing, manufacturing and distributing a consumer health care product, the FC2 </font><font style="display: inline;">Female Condom/FC2 Internal Condom® (“FC2”)</font><font style="display: inline;">.  The completion of the APP Acquisition transitioned the Company into a biopharmaceutical company </font><font style="display: inline;">focused on oncology and urology</font><font style="display: inline;"> with multiple drug products under clinical development.  Most of the Company’s net revenues during the three and six months ended March 31, 2019 and 2018 were derived from sales of FC2.  </font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">:  </font><font style="display: inline;">Certain prior period amounts in the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Cash concentration</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company’s cash is maintained primarily in three financial institutions, located in Chicago, Illinois, London, England and Kuala Lumpur, Malaysia.</font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Restricted cash</font><font style="display: inline;">: Restricted cash relates to security provided to one of the Company’s U.K. banks for performance bonds issued in favor of customers. The Company has a facility of </font><font style="display: inline;">$250,000</font><font style="display: inline;"> for such performance bonds.  Such security has been extended infrequently and only on occasions where it has been a contract term expressly stipulated as an absolute requirement by the customer or its provider of funds. The expiration of the bond is defined by the completion of the event such as, but not limited to, a period of time after the product has been distributed or expiration of the product shelf life.  The Company had </font><font style="display: inline;">no</font><font style="display: inline;"> restricted cash at March 31, 2019. Restricted cash was approximately </font><font style="display: inline;">$135,000</font><font style="display: inline;"> at September 30, 2018 and is included in cash on the accompanying unaudited condensed consolidated balance sheets</font><font style="display: inline;color:#FF0000;">.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#FF0000;text-decoration:underline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Patents and trademarks</font><font style="display: inline;">: The costs for patents and trademarks are expensed when incurred.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Deferred financing costs</font><font style="display: inline;">:</font><font style="display: inline;font-weight:bold;font-style:italic;"> </font><font style="display: inline;">Costs incurred in connection with the </font><font style="display: inline;">common stock purchase agreement discussed in Note 8 </font><font style="display: inline;">have been included in other assets on the accompanying unaudited condensed consolidated balance sheets at March 31, 2019 and September 30, 2018. When shares of the Company’s common stock are sold under the common stock purchase agreement, a pro-rata portion of the deferred costs is recorded to additional paid-in-capital. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">As discussed in Note 8, in connection with the </font><font style="display: inline;">common stock offering that closed on October 1, 2018, we incurred c</font><font style="display: inline;">osts </font><font style="display: inline;">of approximately </font><font style="display: inline;">$190,000</font><font style="display: inline;"> through September 30, 2018. This amount was included in </font><font style="display: inline;">other assets on the accompanying unaudited condensed consolidated balance sheet at September 30, 2018. These costs were charged to additional paid-in capital in the six months ended March 31, 2019 after the common stock offering was closed.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">Costs incurred in connection with the </font><font style="display: inline;">issuance of debt discussed in Note 7 are presented as a reduction of the debt on the accompanying unaudited condensed consolidated balance sheets at March 31, 2019 and September 30, 2018. These issuance costs are being amortized using the effective interest method over the expected repayment period of the debt, which is currently estimated to occur in the third quarter of fiscal 2021. The amortization is included in interest expense on the accompanying unaudited condensed consolidated statements of operations.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Fair value measurements</font><font style="display: inline;">: Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 –</font><font style="display: inline;font-style:italic;"> Fair Value Measurements and Disclosures,</font><font style="display: inline;"> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC Topic 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to us as of the reporting dates. Accordingly, the estimates presented in the accompanying unaudited condensed consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. See Note 3 </font><font style="display: inline;">for a discussion of fair value measurements</font><font style="display: inline;">.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term nature of these instruments. The carrying value of long-term debt, taking into consideration debt discounts and related derivative instruments, is estimated to approximate fair value.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Unearned revenue</font><font style="display: inline;">: The Company records an unearned revenue liability if a customer pays consideration before the Company transfers the product to the customer under the terms of a contract. Unearned revenue is recognized as revenue after control of the product is transferred to the customer and all revenue recognition criteria have been met.  The Company had no unearned revenue at March 31, 2019. Unearned revenue at September 30, 2018 was approximately </font><font style="display: inline;">$187,000</font><font style="display: inline;color:#000000;"> </font><font style="display: inline;">and was comprised of sales made to a large distributor who has the right to return product under certain conditions. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Derivative instruments</font><font style="display: inline;">: The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company reviews the terms of debt instruments it enters into to determine whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as derivative financial instruments. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. Liabilities incurred in connection with an embedded derivative are discussed in Note 7.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Revenue recognition</font><font style="display: inline;">: Revenue is recognized when control of the promised goods is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The Company generates nearly all of its revenue from direct product sales. Revenue from direct product sales is generally recognized when the customer obtains control of the product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Sales taxes and other similar taxes that the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company does not typically have significant unusual payment terms beyond </font><font style="display: inline;">120</font><font style="display: inline;"> days in its contracts with customers. See Note 4 for additional information regarding credit terms.</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The amount of consideration the Company ultimately receives varies depending upon sales discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The estimate of variable consideration requires significant judgment. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an </font><font style="display: inline;color:#000000;">assessment of current contract sales terms and historical payment experience.</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">Product returns are typically not significant because returns are generally not allowed unless the product is damaged at time of receipt.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Research and development costs</font><font style="display: inline;">: Research and development costs are expensed as they are incurred and include salaries and benefits, clinical trial costs and contract services. Nonrefundable advance payments made for goods or services to be used in research and development activities are deferred and capitalized until the goods have been delivered or the related services have been performed. If the goods are no longer expected to be delivered or the services are no longer expected to be performed, the Company would be required to expense the related capitalized advance payments. The Company did not have any capitalized nonrefundable advance payments as of March 31, 2019 and September 30, 2018.</font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company records estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. These costs are a significant component of the Company’s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled and the rate of patient enrollments may vary from the Company’s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company’s accruals could materially affect the Company’s results of operations. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Share-based compensation</font><font style="display: inline;">: The Company recognizes share-based compensation expense in connection with its share-based awards based on the estimated fair value of the awards on the date of grant, on a straight-line basis over the vesting period. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including estimates of the expected life of the share-based award, stock price volatility and risk-free interest rates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Advertising</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company's policy is to expense advertising costs as incurred. Advertising costs were immaterial to the Company’s results of operations for the three and six months ended March 31, 2019 and 2018.</font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"> </font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Income taxes</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company files separate income tax returns for its foreign subsidiaries. FASB ASC Topic 740 requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are also provided for carryforwards for income tax purposes. In addition, the amount of any future tax benefits is reduced by a valuation allowance to the extent such benefits are not expected to be realized.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Foreign currency translation and operations</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: Effective October 1, 2009, the Company determined that there were significant changes in facts and circumstances, triggering an evaluation of its subsidiaries’ functional currency.  The evaluation indicated that the U.S. dollar is the currency with the most significant influence upon the subsidiaries.  Because all of the U.K. subsidiary's future sales and cash flows would be denominated in U.S. dollars following the October 2009 cessation of production of the Company’s first-generation product, FC1, the U.K. subsidiary adopted the U.S. dollar as its functional currency effective October 1, 2009. As the Malaysia subsidiary is a direct and integral component of the U.K. parent’s operations, it, too, adopted the U.S. dollar as its functional currency as of October 1, 2009. The consistent use of the U.S. dollar as the functional currency across the Company reduces its foreign currency risk and stabilizes its operating results. The cumulative foreign currency translation loss included in accumulated other comprehensive loss was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million as of March 31, 2019 and September 30, 2018. Assets located outside of the U.S. totaled approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$5.0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$5.2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million at March 31, 2019 and September 30, 2018, respectively.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">    </font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Other comprehensive loss</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net loss.  Although certain changes in assets and liabilities, such as foreign currency translation adjustments, are reported as a separate component of the equity section of the accompanying unaudited condensed consolidated balance sheets, these items, along with net loss, are components of other comprehensive loss.</font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">The U.S. parent company and its U.K. subsidiary routinely purchase inventory produced by its Malaysia subsidiary for sale to their respective customers. These intercompany trade accounts are eliminated in consolidation. The Company’s policy and intent is to settle the intercompany trade account on a current basis.  Since the U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currencies effective October 1, 2009, no foreign currency gains or losses from intercompany trade are recognized.  For the three and six months ended March 31, 2019 and 2018, comprehensive loss is equivalent to the reported net loss. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">    </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Recently Issued Accounting Pronouncements</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, </font><font style="display: inline;font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606)</font><font style="display: inline;color:#000000;">.  This new accounting guidance on revenue recognition provides for a single five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. The new guidance also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts.  The Company adopted the new guidance on October 1, 2018 using the modified retrospective method and elected to apply the guidance only to contracts that were not completed as of the date of adoption. The adoption of this guidance did not have a material effect on our consolidated financial statements and related disclosures. See discussion above for disclosures relating to the Company's revenue recognition.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In February 2016, the FASB issued ASU 2016-02, </font><font style="display: inline;font-style:italic;">Leases (Topic 842)</font><font style="display: inline;">,  </font><font style="display: inline;color:#000000;">which requires that lessees recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet. ASU 2016-02 distinguishes leases as either a finance lease or an operating lease, which affects how the leases are measured and presented in the statement of operations and statement of cash flows, and requires disclosure of</font><font style="display: inline;"> key information about leasing arrangements.  ASU 2016-02 </font><font style="display: inline;color:#000000;">is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required upon adoption.</font><font style="display: inline;">  Early adoption is permitted. I</font><font style="display: inline;color:#000000;">n July 2018, the FASB issued ASU No. 2018-10, </font><font style="display: inline;font-style:italic;color:#000000;">Codification Improvements to Topic 842, Leases</font><font style="display: inline;color:#000000;"> to clarify the implementation guidance and ASU No. 2018-11, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842) Targeted Improvements</font><font style="display: inline;color:#000000;">. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. </font><font style="display: inline;">I</font><font style="display: inline;color:#000000;">n December 2018, the FASB issued ASU 2018-20, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842): Narrow-Scope Improvements for Lessors</font><font style="display: inline;color:#000000;"> to address certain implementation issues facing lessors when adopting ASU 2016-02. </font><font style="display: inline;">I</font><font style="display: inline;color:#000000;">n March 2019, the FASB issued ASU 2019-01, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842): Codification Improvements</font><font style="display: inline;color:#000000;"> to address, among other things, certain transition disclosure requirements subsequent to the adoption of ASU 2016-02. The Company will adopt the new accounting standard </font><font style="display: inline;">on October 1, 2019 and intends to elect certain </font><font style="display: inline;color:#000000;">practical expedients, including the optional transition method that allows for the application of the new standard at its adoption date with no restatement of prior period amounts</font><font style="display: inline;">.  </font><font style="display: inline;color:#000000;">We have begun to identify our significant lease contracts and are in the process of </font><font style="display: inline;">evaluating the effect of the new guidance on our consolidated financial statements and related disclosures. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In November 2016, the FASB issued ASU 2016-18, </font><font style="display: inline;font-style:italic;">Statement of Cash Flows</font><font style="display: inline;"> </font><font style="display: inline;font-style:italic;">(Topic 230):</font><font style="display: inline;"> </font><font style="display: inline;font-style:italic;">Restricted Cash</font><font style="display: inline;">. The purpose of ASU 2016-18 is to clarify guidance and presentation related to restricted cash in the statements of cash flows as well as increased disclosure requirements. It requires beginning-of-period and end-of-period total amounts shown on the statements of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents. We adopted ASU 2016-18 effective October 1, 2018. The adoption of ASU 2016-18 did not have a material effect on the presentation of our consolidated statements of cash flows or related disclosures.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In January 2017, the FASB issued ASU 2017-04, </font><font style="display: inline;font-style:italic;color:#000000;">Intangibles - Goodwill and Other Topics </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 350)</font><font style="display: inline;font-style:italic;color:#000000;">: Simplifying the Test for Goodwill Impairment</font><font style="display: inline;color:#000000;">. The purpose of ASU 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect the adoption of ASU 2017-04 to have a material effect on our financial position or results of operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In May 2017, the FASB issued ASU 2017-09, </font><font style="display: inline;font-style:italic;color:#000000;">Compensation - Stock Compensation </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 718)</font><font style="display: inline;font-style:italic;color:#000000;">: Scope of Modification Accounting</font><font style="display: inline;color:#000000;">. The purpose of ASU 2017-09 is to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. </font><font style="display: inline;color:#000000;">The amendments in ASU 2017-09 should be applied prospectively to an award modified on or after the adoption date. We adopted </font><font style="display: inline;color:#000000;">ASU 2017-09 effective October 1, 2018. The adoption of ASU 2017-09 did not have a material effect on our financial position or results of operations.  </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In June 2018, the FASB issued ASU 2018-07, </font><font style="display: inline;font-style:italic;color:#000000;">Compensation - Stock Compensation </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 718)</font><font style="display: inline;font-style:italic;color:#000000;">: Improvements to Nonemployee Share-Based Payment Accounting</font><font style="display: inline;color:#000000;">. The purpose of ASU 2018-07 is to expand the scope of </font><font style="display: inline;font-style:italic;color:#000000;">Topic 718, Compensation—Stock Compensation</font><font style="display: inline;color:#000000;"> (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 will be effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than the Company’s adoption date of </font><font style="display: inline;font-style:italic;color:#000000;">Topic 606, Revenue from Contracts with Customers</font><font style="display: inline;color:#000000;">. The Company has issued share-based payments to nonemployees in the past but is not able to predict the amount of future share-based payments to nonemployees, if any. The adoption of ASU 2018-07 is not expected to have a material effect on our financial position or results of operations but should simplify the process by which the Company measures compensation expense for share-based payments to nonemployees.</font><font style="display: inline;font-weight:bold;"> </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In August 2018, the FASB issued ASU 2018-13, </font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820): Disclosure Framework – Change to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;">. ASU 2018-13 </font><font style="display: inline;color:#000000;">modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted</font><font style="display: inline;color:#000000;">. The adoption of ASU 2018-13 is not expected to have a material effect on our financial position or results of operations </font><font style="display: inline;color:#000000;">as it modifies disclosure requirements only.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q3	us-gaap	Cash Cash	3759509
CY2019Q1	us-gaap	Cash Cash	5896536
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3277602
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8972498
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3759509
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5896536
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5694896
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2137027
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	77000000
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	154000000
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57468660
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64968184
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55284956
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62784480
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	574687
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	649682
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4034035
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Cash concentration</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company’s cash is maintained primarily in three financial institutions, located in Chicago, Illinois, London, England and Kuala Lumpur, Malaysia.</font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2647928
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1374936
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4094993
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2367264
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4653558
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	24710
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	88161
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	210594
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	187159
CY2018Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	8543758
CY2019Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	8570150
CY2018Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8543758
CY2019Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8570150
CY2019Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	17586
CY2019Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	759875
CY2019Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1700
CY2019Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	54706
CY2018Q3	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	844758
CY2019Q1	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	895860
CY2018Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	844758
CY2019Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	895860
CY2019Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7316
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018Q3	us-gaap	Inventory Net InventoryNet	2302030
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-21000
CY2018Q1	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-21000
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-403000
CY2019Q1	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-628000
CY2018Q3	us-gaap	Goodwill Goodwill	6878932
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3340000
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2426000
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2829000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	422271
CY2019Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	576888
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2900000
CY2019Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2900000
CY2019Q1	us-gaap	Goodwill Goodwill	6878932
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2477729
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2323112
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-116532
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-63077
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-41187
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-23643
CY2018Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	3319000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	21000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	403000
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
	us-gaap	Gross Profit GrossProfit	2511557
CY2018Q1	us-gaap	Gross Profit GrossProfit	1197936
	us-gaap	Gross Profit GrossProfit	9252931
CY2019Q1	us-gaap	Gross Profit GrossProfit	4608851
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12636839
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5133634
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6065168
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4008868
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4548469
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1302416
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-142147
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-187159
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-21000
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-403000
CY2019Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	20900000
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20477729
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20323112
	us-gaap	Interest Expense InterestExpense	350595
CY2018Q1	us-gaap	Interest Expense InterestExpense	350595
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	821133
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	748095
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62485
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	73589
CY2018Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	20477729
CY2019Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	20323112
CY2018Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	20900000
	us-gaap	Interest Expense InterestExpense	2536695
CY2019Q1	us-gaap	Interest Expense InterestExpense	1258272
CY2019Q1	us-gaap	Inventory Net InventoryNet	2998201
CY2018Q3	us-gaap	Liabilities Liabilities	18971221
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	117665
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25167
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1651193
CY2019Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1028063
	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-187000
	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	80386
CY2018Q1	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	50981
	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-3527
CY2019Q1	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4830
CY2018Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1077736
CY2019Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-841862
	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	12702
CY2018Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	8702
	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	4783
CY2019Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	2364
	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	122574
CY2018Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	101032
	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-22863
CY2019Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1025
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-948395
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-301863
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	853949
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-656527
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3250664
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54603
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	375957
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-391011
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1148345
CY2019Q1	us-gaap	Liabilities Liabilities	17468037
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25637
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1942
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	174357
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	776178
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48452639
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51012054
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13552927
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11272127
CY2018Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	6692718
CY2019Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	5836615
CY2018Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	2701570
CY2019Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	2717934
CY2019Q1	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	10000000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9880000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6140250
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1913
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-644
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4183191
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4002579
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-4257152
	us-gaap	Net Income Loss NetIncomeLoss	-8088370
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-3831218
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-2148798
	us-gaap	Net Income Loss NetIncomeLoss	-6182833
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-503707
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-437084
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2928851
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1884278
	us-gaap	Operating Expenses OperatingExpenses	14644689
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	5894486
	us-gaap	Operating Expenses OperatingExpenses	12389248
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	6733441
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12133132
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4696550
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3136317
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2124590
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	965152
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-600000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-600000
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2465657
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2472422
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-350595
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2536695
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15580
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2412
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52031
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5272410
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2910587
	us-gaap	Share Based Compensation ShareBasedCompensation	619302
	us-gaap	Share Based Compensation ShareBasedCompensation	913465
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	120000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1913
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	644
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	77000000
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	154000000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1220908
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">:  </font><font style="display: inline;">Certain prior period amounts in the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9131967
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	10000000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4305970
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4306019
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	404552
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320802
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3764137
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	3191717
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4035162
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2076794
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	135000
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58201651
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64384484
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5159485
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2572872
CY2019Q1	veru	Deferred Tax Assets Foreign Capital Allowance DeferredTaxAssetsForeignCapitalAllowance	102098
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Monte Carlo Simulation
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13347924
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6976115
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7116838
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3822854
CY2018Q3	veru	Allowance For Sales And Payment Term Discounts AllowanceForSalesAndPaymentTermDiscounts	37900
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6845390
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3817692
CY2019Q1	veru	Allowance For Sales And Payment Term Discounts AllowanceForSalesAndPaymentTermDiscounts	13309
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	44750588
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	41331218
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	29481418
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	36881843
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	33544017
CY2017Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	347081
CY2018Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9131967
CY2017Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	207454
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	411848
CY2018Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	417256
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	496209
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	200000
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	2183704
CY2019Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	2183704
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	7806605
CY2019Q1	us-gaap	Treasury Stock Value TreasuryStockValue	7806605
CY2019Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1600000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53253901
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53355944
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62659352
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62767258
CY2018Q3	veru	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	981357
CY2019Q1	veru	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	437928
	veru	Allowance For Doubtful Accounts Receivable Net Write Offs And Recoveries AllowanceForDoubtfulAccountsReceivableNetWriteOffsAndRecoveries	5000
CY2019Q1	veru	Income Tax Reconciliation Effect Of Deemed Dividends IncomeTaxReconciliationEffectOfDeemedDividends	32318
	veru	Increase In Deferred Assets From Accrued Expenses IncreaseInDeferredAssetsFromAccruedExpenses	77840
	veru	Shares Issued In Connection With Common Stock Purchase SharesIssuedInConnectionWithCommonStockPurchase	347081
CY2018	veru	Stock Issuance Costs Incurred StockIssuanceCostsIncurred	190000
CY2018Q1	veru	Stock Issuance Costs Payable StockIssuanceCostsPayable	143943
	veru	Depreciation And Other Amortization DepreciationAndOtherAmortization	88239
	veru	Depreciation And Other Amortization DepreciationAndOtherAmortization	84394
	veru	Income Tax Reconciliation Effect Of Deemed Dividends IncomeTaxReconciliationEffectOfDeemedDividends	63627
	veru	Number Of Class Action Lawsuits Filed NumberOfClassActionLawsuitsFiled	2
	veru	Provision Charges To Expenses ProvisionChargesToExpenses	3058
CY2018Q3	veru	Residual Royalty Agreement Noncurrent ResidualRoyaltyAgreementNoncurrent	1753805
CY2019Q1	veru	Residual Royalty Agreement Noncurrent ResidualRoyaltyAgreementNoncurrent	2341522

Files In Submission

Name	View Source	Status
0000863894-19-000007-index-headers.html	Edgar Link	pending
0000863894-19-000007-index.html	Edgar Link	pending
0000863894-19-000007.txt	Edgar Link	pending
0000863894-19-000007-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
veru-20190331.xml	Edgar Link	completed
veru-20190331.xsd	Edgar Link	pending
veru-20190331x10q.htm	Edgar Link	pending
veru-20190331xex10_1.htm	Edgar Link	pending
veru-20190331xex10_3.htm	Edgar Link	pending
veru-20190331xex31_1.htm	Edgar Link	pending
veru-20190331xex31_2.htm	Edgar Link	pending
veru-20190331xex32_1.htm	Edgar Link	pending
veru-20190331_cal.xml	Edgar Link	unprocessable
veru-20190331_def.xml	Edgar Link	unprocessable
veru-20190331_lab.xml	Edgar Link	unprocessable
veru-20190331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VERU
Veru Inc Stock $veru

2019 Q2 Form 10-Q Financial Statement

#000086389419000007 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERU Veru Inc Stock $veru

2019 Q2 Form 10-Q Financial Statement

#000086389419000007 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERU
Veru Inc Stock $veru